These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1203 related articles for article (PubMed ID: 21536936)
1. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936 [TBL] [Abstract][Full Text] [Related]
2. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma. Chipps BE; Figliomeni M; Spector S Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179 [TBL] [Abstract][Full Text] [Related]
3. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM; J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355 [TBL] [Abstract][Full Text] [Related]
4. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960 [TBL] [Abstract][Full Text] [Related]
6. Omalizumab for asthma in adults and children. Normansell R; Walker S; Milan SJ; Walters EH; Nair P Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989 [TBL] [Abstract][Full Text] [Related]
7. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320 [TBL] [Abstract][Full Text] [Related]
8. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD; Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M; Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408 [TBL] [Abstract][Full Text] [Related]
12. Spotlight on omalizumab in allergic asthma. Bang LM; Plosker GL BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425 [TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Omalizumab therapy for patients with severe asthma. Ann Intern Med; 2011 May; 154(9):I28. PubMed ID: 21536934 [No Abstract] [Full Text] [Related]
14. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757 [TBL] [Abstract][Full Text] [Related]
17. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Greenstone IR; Ni Chroinin MN; Masse V; Danish A; Magdalinos H; Zhang X; Ducharme FM Cochrane Database Syst Rev; 2005 Oct; (4):CD005533. PubMed ID: 16235409 [TBL] [Abstract][Full Text] [Related]
18. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258 [TBL] [Abstract][Full Text] [Related]
19. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience. Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001 [TBL] [Abstract][Full Text] [Related]
20. Omalizumab: a review of its use in the management of allergic asthma. Bang LM; Plosker GL Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]